These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 10403477)

  • 1. Factor H and disease: a complement regulator affects vital body functions.
    Zipfel PF; Hellwage J; Friese MA; Hegasy G; Jokiranta ST; Meri S
    Mol Immunol; 1999; 36(4-5):241-8. PubMed ID: 10403477
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The factor H protein family.
    Zipfel PF; Jokiranta TS; Hellwage J; Koistinen V; Meri S
    Immunopharmacology; 1999 May; 42(1-3):53-60. PubMed ID: 10408366
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Attachment of the soluble complement regulator factor H to cell and tissue surfaces: relevance for pathology.
    Józsi M; Manuelian T; Heinen S; Oppermann M; Zipfel PF
    Histol Histopathol; 2004 Jan; 19(1):251-8. PubMed ID: 14702193
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The complement fitness factor H: role in human diseases and for immune escape of pathogens, like pneumococci.
    Zipfel PF; Hallström T; Hammerschmidt S; Skerka C
    Vaccine; 2008 Dec; 26 Suppl 8():I67-74. PubMed ID: 19388168
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Complement factor H: physiology and pathophysiology.
    Zipfel PF
    Semin Thromb Hemost; 2001 Jun; 27(3):191-9. PubMed ID: 11446652
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Primary glomerulonephritis with isolated C3 deposits: a new entity which shares common genetic risk factors with haemolytic uraemic syndrome.
    Servais A; Frémeaux-Bacchi V; Lequintrec M; Salomon R; Blouin J; Knebelmann B; Grünfeld JP; Lesavre P; Noël LH; Fakhouri F
    J Med Genet; 2007 Mar; 44(3):193-9. PubMed ID: 17018561
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Complement activation in diseases presenting with thrombotic microangiopathy.
    Meri S
    Eur J Intern Med; 2013 Sep; 24(6):496-502. PubMed ID: 23743117
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Uncontrolled C3 activation causes membranoproliferative glomerulonephritis in mice deficient in complement factor H.
    Pickering MC; Cook HT; Warren J; Bygrave AE; Moss J; Walport MJ; Botto M
    Nat Genet; 2002 Aug; 31(4):424-8. PubMed ID: 12091909
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Factor H family proteins and human diseases.
    Józsi M; Zipfel PF
    Trends Immunol; 2008 Aug; 29(8):380-7. PubMed ID: 18602340
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hemolytic uremic syndrome: a factor H mutation (E1172Stop) causes defective complement control at the surface of endothelial cells.
    Heinen S; Józsi M; Hartmann A; Noris M; Remuzzi G; Skerka C; Zipfel PF
    J Am Soc Nephrol; 2007 Feb; 18(2):506-14. PubMed ID: 17229916
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [The role of complement in physiology and pathology].
    Klaska I; Nowak JZ
    Postepy Hig Med Dosw (Online); 2007; 61():167-77. PubMed ID: 17410057
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Complement factor H related proteins in immune diseases.
    Skerka C; Zipfel PF
    Vaccine; 2008 Dec; 26 Suppl 8():I9-14. PubMed ID: 19388158
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A novel C3 mutation causing increased formation of the C3 convertase in familial atypical hemolytic uremic syndrome.
    Sartz L; Olin AI; Kristoffersson AC; Ståhl AL; Johansson ME; Westman K; Fremeaux-Bacchi V; Nilsson-Ekdahl K; Karpman D
    J Immunol; 2012 Feb; 188(4):2030-7. PubMed ID: 22250080
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Secreted aspartic protease 2 of Candida albicans inactivates factor H and the macrophage factor H-receptors CR3 (CD11b/CD18) and CR4 (CD11c/CD18).
    Svoboda E; Schneider AE; Sándor N; Lermann U; Staib P; Kremlitzka M; Bajtay Z; Barz D; Erdei A; Józsi M
    Immunol Lett; 2015 Nov; 168(1):13-21. PubMed ID: 26306739
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An interactive web database of factor H-associated hemolytic uremic syndrome mutations: insights into the structural consequences of disease-associated mutations.
    Saunders RE; Goodship TH; Zipfel PF; Perkins SJ
    Hum Mutat; 2006 Jan; 27(1):21-30. PubMed ID: 16281287
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Factor H and atypical hemolytic uremic syndrome: mutations in the C-terminus cause structural changes and defective recognition functions.
    Józsi M; Heinen S; Hartmann A; Ostrowicz CW; Hälbich S; Richter H; Kunert A; Licht C; Saunders RE; Perkins SJ; Zipfel PF; Skerka C
    J Am Soc Nephrol; 2006 Jan; 17(1):170-7. PubMed ID: 16338962
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Host recognition and target differentiation by factor H, a regulator of the alternative pathway of complement.
    Pangburn MK
    Immunopharmacology; 2000 Aug; 49(1-2):149-57. PubMed ID: 10904114
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Autoantibodies in haemolytic uraemic syndrome (HUS).
    Skerka C; Józsi M; Zipfel PF; Dragon-Durey MA; Fremeaux-Bacchi V
    Thromb Haemost; 2009 Feb; 101(2):227-32. PubMed ID: 19190803
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Shiga toxin activates complement and binds factor H: evidence for an active role of complement in hemolytic uremic syndrome.
    Orth D; Khan AB; Naim A; Grif K; Brockmeyer J; Karch H; Joannidis M; Clark SJ; Day AJ; Fidanzi S; Stoiber H; Dierich MP; Zimmerhackl LB; Würzner R
    J Immunol; 2009 May; 182(10):6394-400. PubMed ID: 19414792
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Autoantibodies to complement components in C3 glomerulopathy and atypical hemolytic uremic syndrome.
    Józsi M; Reuter S; Nozal P; López-Trascasa M; Sánchez-Corral P; Prohászka Z; Uzonyi B
    Immunol Lett; 2014 Aug; 160(2):163-71. PubMed ID: 24491679
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.